We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glutamatergic Mechanisms: Aim2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05401227
Recruitment Status : Not yet recruiting
First Posted : June 2, 2022
Last Update Posted : August 19, 2022
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Joshua Kantrowitz, New York State Psychiatric Institute

Tracking Information
First Submitted Date  ICMJE May 27, 2022
First Posted Date  ICMJE June 2, 2022
Last Update Posted Date August 19, 2022
Estimated Study Start Date  ICMJE December 15, 2022
Estimated Primary Completion Date August 15, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 1, 2022)
  • Final PharmacoBOLD signals in pre-specified ROIs [ Time Frame: Baseline and Day 4 ]
    Changes in ketamine-induced PharmacoBOLD fMRI signals in pre-specified ROIs (anterior cingulate cortex) following administrations of TS-134
  • Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Baseline and Day 4 ]
    Changes in BPRS scores following administrations of TS-134
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Glutamatergic Mechanisms: Aim2
Official Title  ICMJE Glutamatergic Mechanisms of Psychosis and Target Engagement: Aim2
Brief Summary

This is a randomized, double-blind, and placebo controlled. 120 HV will be randomized to one of three ketamine arms, delivered in a bolus dose over one minute: low (0.06 mg/kg), medium (0.125 mg/kg), and high (0.23 mg/kg).

Within each ketamine arm, subjects will be randomized to 4 days of TS-134 20 mg or placebo in a 5:3 ratio (25 TS-134:15 placebo). Following an outpatient Screening Period (up to 31 days), eligible subjects will undergo a 5-day inpatient Treatment Period. During the study, each subject will undergo a total of two ketamine sessions: a first session during the Screening Period and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart. All randomized subjects will be dosed with TS-134 or placebo daily in a fed state for 4 days during the study, titrated to 20 mg over the first 2 days.

Detailed Description

Schizophrenia (Sz) is associated with psychotic symptoms, such as hearing voices and paranoid beliefs that remain partially or fully refractory to standard antipsychotic medications for ~2/3 of patients. Alternative, glutamatergic approaches for treatment development have been proposed but have not yet led to FDA-approved medications. Moreover, several glutamate-targeted medications, such as pomaglumetad (POMA), have failed in pivotal clinical trials despite robust effectiveness in preclinical models. A major barrier to effective glutamatergic treatment development is the absence of validated measures for target engagement that can identify effective compounds and guide dose selection. Target" refers to a factor that an intervention is intended to modify, leading to improvement in symptoms, and target engagement biomarkers are a measure of the ability of the intervention to "engage" the target.

As part of the recently completed NIMH multicenter FAST-PS initiative and a parallel industry sponsored project, we evaluated ketamine-induced pharmacoBOLD (phBOLD) in healthy volunteers (HV) as a potential target engagement biomarker for development of metabotropic glutamate (mGluR2/3) agonists, as a prelude to planned studies in Sz. BOLD imaging indirectly measures brain energy, as a proxy for glutamate target engagement.

The structure of the R01 grant funding this protocol was split into three studies, specific aim (SA) 1, 2 and 3. In FAST-PS, a high dose of ketamine (0.23 mg/kg) was used in order to produce robust pharmacological effects.

Under SA1, which was conducted under IRB 8063, this dose was titrated downward in across two phBOLD sessions in HV in order to determine the lowest dose of ketamine that still produces a phBOLD response of Cohen's d≥1.5, hypothesizing that this dose would provide the best signal to noise for use in SA2. The study was conducted in groups of 10 subject per dose cohort, and the analysis supports using a low dose of 0.06 mg/kg for SA2.

SA2 experiments are modeled after our preliminary TS-134 studies. SA2 will be randomized, double-blind, and placebo controlled. 120 HV will be randomized to one of three ketamine arms: low, medium, and high. Based on SA1, the low dose will be 0.06 mg/kg. The medium dose, 0.125 mg/kg, is based the previously published mGluR2/3 target engagement study and the high dose is equal to 0.23 mg/kg, the same as in the FAST-PS study.

Within each ketamine arm, subjects will be randomized to 4 days of TS-134 20 mg or placebo in a 5:3 ratio (25 TS-134:15 placebo). Following an outpatient Screening Period (up to 31 days), eligible subjects will undergo a 5-day inpatient Treatment Period. During the study, each subject will undergo a total of two ketamine sessions: a first session during the Screening Period and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart. All randomized subjects will be dosed with TS-134 or placebo daily in a fed state for 4 days during the study, titrated to 20 mg over the first 2 days. As before, subjects' general health and safety status will be confirmed by a phone call following discharge from the Treatment Period. Primary outcomes will be (1) suppression of the phBOLD response and (2) psychiatric symptoms after 4 days of TS-134, relative to ketamine screening session effects.

In parallel, we will evaluate the interactions between glutamate and DA systems using ketamine-induced phBOLD and sLASER MRS to interrogate the glutamate system and neuromelanin MRI (NM-MRI) to interrogate the DA system. These additional measures will be collected at baseline, pre ketamine.

For the 1st 20 subjects, we will not randomize to low dose, and subjects will only receive either high or medium dose. Based on the results of an additional cohort conducted under NCT04589208, we may change the low dose. This description will be modified when NCT04589208 is completed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Subjects will be randomized to one of three ketamine arms. with in each ketamine arm, subjects will be randomized to TS-134 or placebo for 6 total arms.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Double blind
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: Ketamine
    Ketamine during an MRI
  • Drug: Ts-134
    4 days of TS-134 20 mg
  • Drug: Placebo
    4 days of placebo TS-134
Study Arms  ICMJE
  • Experimental: High Ketamine, TS-134
    Two administrations of ketamine 0.23 mg/kg pre post 4 days of TS-134 20 mg
    Interventions:
    • Drug: Ketamine
    • Drug: Ts-134
  • Placebo Comparator: High ketamine, placebo
    Two administrations of ketamine 0.23 mg/kg pre post 4 days of placebo
    Interventions:
    • Drug: Ketamine
    • Drug: Placebo
  • Experimental: Medium Ketamine, TS-134
    Two administrations of ketamine 0.125 mg/kg pre post 4 days of TS-134 20 mg
    Interventions:
    • Drug: Ketamine
    • Drug: Ts-134
  • Placebo Comparator: Medium Ketamine, placebo
    Two administrations of ketamine 0.125 mg/kg pre post 4 days of placebo
    Interventions:
    • Drug: Ketamine
    • Drug: Placebo
  • Experimental: Low Ketamine, TS-134
    Two administrations of ketamine 0.06 mg/kg pre post 4 days of TS-134 20 mg
    Interventions:
    • Drug: Ketamine
    • Drug: Ts-134
  • Placebo Comparator: Low Ketamine, placebo
    Two administrations of ketamine 0.06 mg/kg pre post 4 days of placebo
    Interventions:
    • Drug: Ketamine
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 1, 2022)
120
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 15, 2026
Estimated Primary Completion Date August 15, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age between 18-55
  2. Medically healthy, as assessed by study physician
  3. Capable of understanding the study procedures and able to provide informed consent
  4. Eligible men and women must agree to use a reliable method of birth control (for example, use of oral contraceptives or Norplant; a reliable barrier method of birth control diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) during the study. Women who are post-menopausal or otherwise not of childbearing potential are also eligible.

Exclusion Criteria:

  1. Current or past Axis I psychiatric history (including Substance Use Disorder/Alcohol Use Disorder, with the exception of nicotine use disorder)
  2. Positive urine toxicology
  3. History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Subjects who have participated in prior research ketamine studies will be eligible. Subjects can have infusions not more frequently than biweekly, and not more than 1/month on average, therefore subjects entering the study will need to wait one month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.
  4. History of first-degree relative with schizophrenia
  5. Pregnancy or breast-feeding. This exclusion criterion applies only to females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopausal). Must test negative for pregnancy at the time of screening based on a serum pregnancy test.
  6. History of violence, including any history of using a gun, knife, or other weapon with intent to harm someone, as well as a more than one physical fight without a weapon after the age of 18 years old (not including fights that happen during sports competition).
  7. Presence or positive history of significant medical illness, including renal problems (GFR<60), high blood pressure (defined as systolic blood pressure (SBP) > 140 or diastolic blood pressure (DBP) > 90), low blood pressure (SBP < 100, DBP < 60), orthostatic blood pressure at baseline (change in mean arterial pressure [1/3 systolic + 2/3 diastolic] of > 20%), cardiac illness, or clinically significant abnormal screening labs, as determined by the site physician.
  8. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator.
  9. Presence or positive history of neurological illness, including seizures, mental retardation or any other disease/procedure/accident/intervention associated with significant injury to or malfunction of the central nervous system (CNS), or history of significant head injury.
  10. Metal implants, pacemaker, other metal (e.g., shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan.
  11. Medicinal patch, unless removed prior to the MR scan
  12. Claustrophobia
  13. Currently taking any psychotropic medication, including antidepressant medications, benzodiazepines, antipsychotic medications, mood stabilizers, anti-epileptic medications, and stimulants. We will exclude any subject who requires treatment with any psychotropic medication from one of these classes.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Moriah Dadson 6467758496 Moriah.Dadson@nyspi.columbia.edu
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05401227
Other Study ID Numbers  ICMJE 8299
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: NIMH Data archive
Supporting Materials: Study Protocol
Supporting Materials: Informed Consent Form (ICF)
Time Frame: Per NIMH Data archive regulations
Access Criteria: Qualified investigator
Current Responsible Party Joshua Kantrowitz, New York State Psychiatric Institute
Original Responsible Party Same as current
Current Study Sponsor  ICMJE New York State Psychiatric Institute
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Institute of Mental Health (NIMH)
Investigators  ICMJE Not Provided
PRS Account New York State Psychiatric Institute
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP